• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Mosseri Marlio Charles bought $235,647 worth of shares (27,411 units at $8.60) (SEC Form 4)

    5/9/25 6:53:19 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mosseri Marlio Charles

    (Last) (First) (Middle)
    27 RIPPLEVALE GROVE

    (Street)
    LONDON N1 1HS

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Nuvectis Pharma, Inc. [ NVCT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/06/2025 P 2,340 A $8.4 2,886,461(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/06/2025 P 10,104 A $8.64 2,896,565(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/07/2025 P 2,703 A $8.4 2,899,268(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/07/2025 P 9,614 A $8.64 2,908,882(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/08/2025 P 50 A $8.65 2,908,932(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/08/2025 P 100 A $8.65 2,909,032(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/08/2025 P 100 A $8.65 2,909,132(1) I By Emerald Hill Ventures SARL SPF.
    Common Stock 05/08/2025 P 2,400 A $8.65 2,911,532(1) I By Emerald Hill Ventures SARL SPF.
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.
    /s/ Charles Mosseri-Marlio 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod

      5/6/25 8:00:11 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

      Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innova

      4/29/25 4:25:00 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

      Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2025 American Association for Cancer Research Meeting (2025 AACR), taking place from April 25th to April 30th in Chicago, IL. Presentation details are below: Abstract TitlePoster Presentation DetailsFirst in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumorsSession Title First-in-Hu

      3/26/25 8:00:00 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    SEC Filings

    See more
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:20:51 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nuvectis Pharma Inc.

      424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:12:42 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Nuvectis Pharma Inc.

      10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/6/25 4:12:37 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $235,647 worth of shares (27,411 units at $8.60) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/9/25 6:53:19 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $1,200,000 worth of shares (240,000 units at $5.00) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      2/11/25 5:58:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman & CEO Bentsur Ron bought $20,925 worth of shares (4,500 units at $4.65), increasing direct ownership by 0.14% to 3,270,924 units (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      12/26/24 8:00:08 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      11/5/24 10:55:09 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/28/24 8:37:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvectis Pharma Inc.

      SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/6/24 8:47:33 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $235,647 worth of shares (27,411 units at $8.60) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/9/25 6:53:19 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $1,200,000 worth of shares (240,000 units at $5.00) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      2/11/25 5:58:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 10% to 1,643,068 units (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      1/3/25 6:13:05 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Nuvectis Pharma with a new price target

      Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

      4/2/25 8:05:05 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Nuvectis Pharma with a new price target

      Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

      3/17/25 7:40:44 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

      Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

      7/13/22 8:35:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care